In myelodysplastic syndrome, a recent report found significant responses to the combination of a DNMT1 inhibitor and a PDL1 inhibitor in some patients previously resistant to hypomethylating drugs [38]. This evidence concerns the gene CD274 and myelodysplastic syndrome.